{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015454","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.893283+00:00","generated_at":"2026-06-15T22:16:49.133563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"C4 Therapeutics Q1 net loss widens to $34.8M; cash runway into 2025","bullets":["Net loss of $34.8M ($0.71 per share) vs. $31.6M ($0.65) in Q1 2022; revenue dropped to $3.8M from $7.7M.","R&D expense rose to $29.0M (Q1 2022: $26.2M) driven by clinical trial costs for CFT7455, CFT8634, CFT1946.","Cash, equivalents and marketable securities were $305.0M as of March 31, 2023, expected to fund operations into 2025.","Phase 1 dose-escalation data for CFT7455 (monotherapy in multiple myeloma) and CFT8634 (synovial sarcoma) expected in H2 2023.","IND submission for CFT8919 (NSCLC) targeted for H1 2023; first patient dosed in CFT1946 Phase 1/2 trial in January."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015454","json":"https://secwatch.observer/filing/0001628280-23-015454.json","markdown":"https://secwatch.observer/filing/0001628280-23-015454.md","text":"https://secwatch.observer/filing/0001628280-23-015454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023015454/0001628280-23-015454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023015454/cccc-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:16:49.133563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c72c5ead967789c24175f71258055b7ccf6c9d20","claim":"C4 Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $3.8 million, net income $34.8 million, EPS $0.71.","evidence_excerpt":"will participate in the Jefferies Global Healthcare Conference in New York. FIRST QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2023 was $3.8 million, compared to $7.7 million for the first quarter of 2022. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023015454/0001628280-23-015454-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$3.8 million"},{"label":"Net income","value":"$34.8 million"},{"label":"EPS","value":"$0.71"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}